Last reviewed · How we verify
WX-UK1 in combination with Capecitabine
WX-UK1 in combination with Capecitabine is a Small molecule drug developed by Heidelberg Pharma AG. It is currently in Phase 1 development.
At a glance
| Generic name | WX-UK1 in combination with Capecitabine |
|---|---|
| Sponsor | Heidelberg Pharma AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX-UK1 in combination with Capecitabine CI brief — competitive landscape report
- WX-UK1 in combination with Capecitabine updates RSS · CI watch RSS
- Heidelberg Pharma AG portfolio CI
Frequently asked questions about WX-UK1 in combination with Capecitabine
What is WX-UK1 in combination with Capecitabine?
WX-UK1 in combination with Capecitabine is a Small molecule drug developed by Heidelberg Pharma AG.
Who makes WX-UK1 in combination with Capecitabine?
WX-UK1 in combination with Capecitabine is developed by Heidelberg Pharma AG (see full Heidelberg Pharma AG pipeline at /company/heidelberg-pharma-ag).
What development phase is WX-UK1 in combination with Capecitabine in?
WX-UK1 in combination with Capecitabine is in Phase 1.